The effect of nicotine on threat avoidance behaviour in healthy non-smokers.

What Was Tested

This randomized controlled trial looks at Therapeutic nicotine (patch, non-peptide).

This preregistered study examines how acute nicotine influences costly avoidance behaviour in non-smokers.

During acquisition, participants could choose between a safer but longer path to reach their goal or a shorter path (less effort) with a higher chance of receiving an aversive outcome in the form of an electrical stimulus.

Why It Was Studied

Developing adaptive strategies for survival relies on distinguishing danger from safety through aversive learning mechanisms.

Yet, it is unclear if nicotine also impacts one behavioural consequence of aversive learning, which is the avoidance of threats.

Who Took Part

By PubMed's age tags, the people studied were teenagers, young adults and adults, both men and women.

During uninstructed extinction, both paths no longer contained the risk of an aversive outcome and participants could learn this new safety association by trial and error.

How the Study Was Run

The design is described as randomized, double-blind and placebo-controlled.

Random assignment meant chance, not the researchers, decided who got Therapeutic nicotine (patch, non-peptide) and who got the comparison, which limits bias.

Blinding on both sides kept the participants and researchers unaware of who received Therapeutic nicotine (patch, non-peptide).

Some participants received a placebo instead of Therapeutic nicotine (patch, non-peptide), giving a reference point.

Finally, an instructed extinction phase indicated complete safety.

What Was Measured

PubMed files the paper under topics including Nicotine, Avoidance Learning, Non-Smokers, Extinction, Psychological, Fear and Nicotinic Agonists.

Author keywords: Aversive learning.

What This Means in Plain Language

The paper is a randomized, double-blind and placebo-controlled study of Therapeutic nicotine (patch, non-peptide).

Results are reported in around 3 sentences of the abstract; we leave them to the paper itself rather than summarise them.

The publication is from 2025 (Psychopharmacology), a journal based in Germany.

More context: the Therapeutic nicotine (patch, non-peptide) compound page, all human trials.